MedRx Co., Ltd (TYO:4586)

Market Cap	6.65B +80.0%
Revenue (ttm)	120.00M -52.9%
Net Income	-1.26B
EPS	-24.74
Shares Out	59.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	408,500
Average Volume	489,910
Open	114.00
Previous Close	113.00
Day's Range	111.00 - 114.00
52-Week Range	55.00 - 225.00
Beta	0.80
RSI	43.25
Earnings Date	Feb 13, 2026

About MedRx

MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which has completed phase Ib clinical trials for the treatment of spastic paralysis; MRX-9FLT that...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 22
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4586

Financial Performance

In 2024, MedRx's revenue was 257.00 million, an increase of 786.21% compared to the previous year's 29.00 million. Losses were -806.00 million, -13.52% less than in 2023.